Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis
Journal of Acquired Immune Deficiency Syndromes, Volume 50, No. 5, Year 2009
Notification
URL copied to clipboard!
Description
SETTING:: Rifampicin may reduce plasma efavirenz concentrations by inducing the expression of the cytochrome P450 2B6, which metabolizes efavirenz. However, there is no data in pediatric patient populations. METHODS:: We measured plasma efavirenz concentrations in 15 children during and after rifampicin-based antitubercular treatment. They were receiving standard doses of efavirenz as part of antiretroviral treatment. Trough concentration (Cmin) was estimated by extrapolation of the log-linear concentration-time line to 24 hours after the previous dose. RESULTS:: Wide interpatient variation and marked bimodality of efavirenz concentrations were observed. Efavirenz Cmin was not significantly different during vs. after antitubercular treatment (median 0.83 mg/L interquartile range 0.59-6.57 vs. median 0.86 mg/L interquartile range 0.61-3.56; P ≤ 0.125). Nine (60%) and 8 (53%) children had subtherapeutic Cmin (<1 mg/L) during and after antitubercular treatment, respectively. CONCLUSIONS:: Concomitant rifampicin-based antitubercular treatment was not an important determinant of efavirenz concentrations. The substantial proportion of participants with estimated Cmin <1 mg/L could result in the rapid emergence of efavirenz-resistant mutations and treatment failure. Copyright © 2009 by Lippincott Williams & Wilkins.
Authors & Co-Authors
Ren, Yuan
South Africa, Cape Town
University of Cape Town
Nuttall, James J.C.
South Africa, Cape Town
University of Cape Town
Eley, Brian S.
South Africa, Cape Town
University of Cape Town
Meyers, Tammy M.M.
South Africa, Johannesburg
Chris Hani Baragwanath Hospital
Smith, Peter J.D.
South Africa, Cape Town
University of Cape Town
Maartens, Gary Tuberculosis
South Africa, Cape Town
University of Cape Town
McIlleron, Helen Margaret
South Africa, Cape Town
University of Cape Town
Statistics
Citations: 70
Authors: 7
Affiliations: 2
Identifiers
Doi:
10.1097/QAI.0b013e31819c33a3
ISSN:
15254135
Research Areas
Health System And Policy
Infectious Diseases
Maternal And Child Health